

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
MALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	406	23	49	34	32	31	31
Week 2							
Evaluated	406	23	49	34	32	31	31
Retained	381/406 (93.8%)	22/23 (95.7%)	42/49 (85.7%)	34/34 (100.0%)	31/32 (96.9%)	31/31 (100.0%)	26/31 (83.9%)
On Time	376/381 (98.7%)	21/22 (95.5%)	42/42 (100.0%)	33/34 (97.1%)	31/31 (100.0%)	30/31 (96.8%)	25/26 (96.2%)
Late	5/381 (1.3%)	1/22 (4.5%)	0/42 (0.0%)	1/34 (2.9%)	0/31 (0.0%)	1/31 (3.2%)	1/26 (3.8%)
MissedVisit	23/406 (5.7%)	1/23 (4.3%)	7/49 (14.3%)	0/34 (0.0%)	1/32 (3.1%)	0/31 (0.0%)	5/31 (16.1%)
Lost to Follow-up	2/406 (0.5%)	0/23 (0.0%)	0/49 (0.0%)	0/34 (0.0%)	0/32 (0.0%)	0/31 (0.0%)	0/31 (0.0%)
Week 4							
Evaluated	406	23	49	34	32	31	31
Retained	394/406 (97.0%)	22/23 (95.7%)	48/49 (98.0%)	33/34 (97.1%)	32/32 (100.0%)	30/31 (96.8%)	30/31 (96.8%)
On Time	361/394 (91.6%)	16/22 (72.7%)	43/48 (89.6%)	32/33 (97.0%)	28/32 (87.5%)	30/30 (100.0%)	27/30 (90.0%)
Late	33/394 (8.4%)	6/22 (27.3%)	5/48 (10.4%)	1/33 (3.0%)	4/32 (12.5%)	0/30 (0.0%)	3/30 (10.0%)
MissedVisit	9/406 (2.2%)	0/23 (0.0%)	1/49 (2.0%)	1/34 (2.9%)	0/32 (0.0%)	1/31 (3.2%)	1/31 (3.2%)
Lost to Follow-up	3/406 (0.7%)	1/23 (4.3%)	0/49 (0.0%)	0/34 (0.0%)	0/32 (0.0%)	0/31 (0.0%)	0/31 (0.0%)
Week 8							
Evaluated	406	23	49	34	32	31	31
Retained	392/406 (96.6%)	22/23 (95.7%)	47/49 (95.9%)	34/34 (100.0%)	31/32 (96.9%)	29/31 (93.5%)	30/31 (96.8%)
On Time	367/392 (93.6%)	20/22 (90.9%)	43/47 (91.5%)	32/34 (94.1%)	29/31 (93.5%)	29/29 (100.0%)	28/30 (93.3%)
Late	25/392 (6.4%)	2/22 (9.1%)	4/47 (8.5%)	2/34 (5.9%)	2/31 (6.5%)	0/29 (0.0%)	2/30 (6.7%)
MissedVisit	10/406 (2.5%)	0/23 (0.0%)	2/49 (4.1%)	0/34 (0.0%)	1/32 (3.1%)	1/31 (3.2%)	1/31 (3.2%)
Lost to Follow-up	4/406 (1.0%)	1/23 (4.3%)	0/49 (0.0%)	0/34 (0.0%)	0/32 (0.0%)	1/31 (3.2%)	0/31 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.

Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.4 (01FEB2016,1:27)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
MALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	406	23	49	34	32	31	31
Week 16							
Evaluated	406	23	49	34	32	31	31
Retained	381/406 (93.8%)	22/23 (95.7%)	44/49 (89.8%)	34/34 (100.0%)	30/32 (93.8%)	27/31 (87.1%)	28/31 (90.3%)
On Time	343/381 (90.0%)	18/22 (81.8%)	39/44 (88.6%)	32/34 (94.1%)	29/30 (96.7%)	26/27 (96.3%)	24/28 (85.7%)
Late	38/381 (10.0%)	4/22 (18.2%)	5/44 (11.4%)	2/34 (5.9%)	1/30 (3.3%)	1/27 (3.7%)	4/28 (14.3%)
MissedVisit	14/406 (3.4%)	0/23 (0.0%)	5/49 (10.2%)	0/34 (0.0%)	2/32 (6.3%)	3/31 (9.7%)	1/31 (3.2%)
Lost to Follow-up	11/406 (2.7%)	1/23 (4.3%)	0/49 (0.0%)	0/34 (0.0%)	0/32 (0.0%)	1/31 (3.2%)	2/31 (6.5%)
Week 24							
Evaluated	406	23	49	34	32	31	31
Retained	371/406 (91.4%)	22/23 (95.7%)	43/49 (87.8%)	33/34 (97.1%)	28/32 (87.5%)	25/31 (80.6%)	27/31 (87.1%)
On Time	321/371 (86.5%)	22/22 (100.0%)	31/43 (72.1%)	27/33 (81.8%)	26/28 (92.9%)	20/25 (80.0%)	22/27 (81.5%)
Late	50/371 (13.5%)	0/22 (0.0%)	12/43 (27.9%)	6/33 (18.2%)	2/28 (7.1%)	5/25 (20.0%)	5/27 (18.5%)
MissedVisit	24/406 (5.9%)	0/23 (0.0%)	6/49 (12.2%)	1/34 (2.9%)	4/32 (12.5%)	5/31 (16.1%)	2/31 (6.5%)
Lost to Follow-up	11/406 (2.7%)	1/23 (4.3%)	0/49 (0.0%)	0/34 (0.0%)	0/32 (0.0%)	1/31 (3.2%)	2/31 (6.5%)
Week 32							
Evaluated	406	23	49	34	32	31	31
Retained	361/406 (88.9%)	21/23 (91.3%)	45/49 (91.8%)	33/34 (97.1%)	26/32 (81.3%)	27/31 (87.1%)	25/31 (80.6%)
On Time	293/361 (81.2%)	18/21 (85.7%)	33/45 (73.3%)	29/33 (87.9%)	22/26 (84.6%)	18/27 (66.7%)	14/25 (56.0%)
Late	68/361 (18.8%)	3/21 (14.3%)	12/45 (26.7%)	4/33 (12.1%)	4/26 (15.4%)	9/27 (33.3%)	11/25 (44.0%)
MissedVisit	26/406 (6.4%)	1/23 (4.3%)	2/49 (4.1%)	1/34 (2.9%)	5/32 (15.6%)	3/31 (9.7%)	2/31 (6.5%)
Lost to Follow-up	19/406 (4.7%)	1/23 (4.3%)	2/49 (4.1%)	0/34 (0.0%)	1/32 (3.1%)	1/31 (3.2%)	4/31 (12.9%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
MALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	406	23	49	34	32	31	31
Week 40							
Evaluated	406	23	49	34	32	31	31
Retained	353/406 (86.9%)	20/23 (87.0%)	43/49 (87.8%)	32/34 (94.1%)	27/32 (84.4%)	26/31 (83.9%)	24/31 (77.4%)
On Time	283/353 (80.2%)	18/20 (90.0%)	36/43 (83.7%)	27/32 (84.4%)	23/27 (85.2%)	19/26 (73.1%)	13/24 (54.2%)
Late	70/353 (19.8%)	2/20 (10.0%)	7/43 (16.3%)	5/32 (15.6%)	4/27 (14.8%)	7/26 (26.9%)	11/24 (45.8%)
Missed Visit	33/406 (8.1%)	2/23 (8.7%)	4/49 (8.2%)	2/34 (5.9%)	4/32 (12.5%)	4/31 (12.9%)	3/31 (9.7%)
Lost to Follow-up	20/406 (4.9%)	1/23 (4.3%)	2/49 (4.1%)	0/34 (0.0%)	1/32 (3.1%)	1/31 (3.2%)	4/31 (12.9%)
Week 48							
Evaluated	406	23	49	34	32	31	31
Retained	340/406 (83.7%)	19/23 (82.6%)	41/49 (83.7%)	33/34 (97.1%)	26/32 (81.3%)	26/31 (83.9%)	21/31 (67.7%)
On Time	279/340 (82.1%)	17/19 (89.5%)	31/41 (75.6%)	31/33 (93.9%)	20/26 (76.9%)	16/26 (61.5%)	13/21 (61.9%)
Late	61/340 (17.9%)	2/19 (10.5%)	10/41 (24.4%)	2/33 (6.1%)	6/26 (23.1%)	10/26 (38.5%)	8/21 (38.1%)
Missed Visit	34/406 (8.4%)	3/23 (13.0%)	5/49 (10.2%)	1/34 (2.9%)	2/32 (6.3%)	4/31 (12.9%)	6/31 (19.4%)
Lost to Follow-up	32/406 (7.9%)	1/23 (4.3%)	3/49 (6.1%)	0/34 (0.0%)	4/32 (12.5%)	1/31 (3.2%)	4/31 (12.9%)
Week 49							
Evaluated	406	23	49	34	32	31	31
Retained	336/406 (82.8%)	19/23 (82.6%)	35/49 (71.4%)	33/34 (97.1%)	26/32 (81.3%)	25/31 (80.6%)	24/31 (77.4%)
On Time	236/336 (70.2%)	17/19 (89.5%)	21/35 (60.0%)	31/33 (93.9%)	15/26 (57.7%)	15/25 (60.0%)	8/24 (33.3%)
Late	100/336 (29.8%)	2/19 (10.5%)	14/35 (40.0%)	2/33 (6.1%)	11/26 (42.3%)	10/25 (40.0%)	16/24 (66.7%)
Missed Visit	34/406 (8.4%)	3/23 (13.0%)	8/49 (16.3%)	1/34 (2.9%)	2/32 (6.3%)	5/31 (16.1%)	3/31 (9.7%)
Lost to Follow-up	36/406 (8.9%)	1/23 (4.3%)	6/49 (12.2%)	0/34 (0.0%)	4/32 (12.5%)	1/31 (3.2%)	4/31 (12.9%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
MALE**

	Total	Philadelphia, PA	Pittsburgh, PA	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	406	32	25	52	22	27	48
Week 2							
Evaluated	406	32	25	52	22	27	48
Retained	381/406 (93.8%)	30/32 (93.8%)	25/25 (100.0%)	47/52 (90.4%)	20/22 (90.9%)	26/27 (96.3%)	47/48 (97.9%)
On Time	376/381 (98.7%)	30/30 (100.0%)	25/25 (100.0%)	47/47 (100.0%)	19/20 (95.0%)	26/26 (100.0%)	47/47 (100.0%)
Late	5/381 (1.3%)	0/30 (0.0%)	0/25 (0.0%)	0/47 (0.0%)	1/20 (5.0%)	0/26 (0.0%)	0/47 (0.0%)
MissedVisit	23/406 (5.7%)	1/32 (3.1%)	0/25 (0.0%)	5/52 (9.6%)	2/22 (9.1%)	0/27 (0.0%)	1/48 (2.1%)
Lost to Follow-up	2/406 (0.5%)	1/32 (3.1%)	0/25 (0.0%)	0/52 (0.0%)	0/22 (0.0%)	1/27 (3.7%)	0/48 (0.0%)
Week 4							
Evaluated	406	32	25	52	22	27	48
Retained	394/406 (97.0%)	31/32 (96.9%)	25/25 (100.0%)	50/52 (96.2%)	21/22 (95.5%)	24/27 (88.9%)	48/48 (100.0%)
On Time	361/394 (91.6%)	30/31 (96.8%)	25/25 (100.0%)	43/50 (86.0%)	20/21 (95.2%)	24/24 (100.0%)	43/48 (89.6%)
Late	33/394 (8.4%)	1/31 (3.2%)	0/25 (0.0%)	7/50 (14.0%)	1/21 (4.8%)	0/24 (0.0%)	5/48 (10.4%)
MissedVisit	9/406 (2.2%)	0/32 (0.0%)	0/25 (0.0%)	2/52 (3.8%)	1/22 (4.5%)	2/27 (7.4%)	0/48 (0.0%)
Lost to Follow-up	3/406 (0.7%)	1/32 (3.1%)	0/25 (0.0%)	0/52 (0.0%)	0/22 (0.0%)	1/27 (3.7%)	0/48 (0.0%)
Week 8							
Evaluated	406	32	25	52	22	27	48
Retained	392/406 (96.6%)	30/32 (93.8%)	25/25 (100.0%)	50/52 (96.2%)	21/22 (95.5%)	25/27 (92.6%)	48/48 (100.0%)
On Time	367/392 (93.6%)	30/30 (100.0%)	24/25 (96.0%)	43/50 (86.0%)	21/21 (100.0%)	25/25 (100.0%)	43/48 (89.6%)
Late	25/392 (6.4%)	0/30 (0.0%)	1/25 (4.0%)	7/50 (14.0%)	0/21 (0.0%)	0/25 (0.0%)	5/48 (10.4%)
MissedVisit	10/406 (2.5%)	1/32 (3.1%)	0/25 (0.0%)	2/52 (3.8%)	1/22 (4.5%)	1/27 (3.7%)	0/48 (0.0%)
Lost to Follow-up	4/406 (1.0%)	1/32 (3.1%)	0/25 (0.0%)	0/52 (0.0%)	0/22 (0.0%)	1/27 (3.7%)	0/48 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
MALE**

	Total	Philadelphia, PA	Pittsburgh, PA	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	406	32	25	52	22	27	48
Week 16							
Evaluated	406	32	25	52	22	27	48
Retained	381/406 (93.8%)	30/32 (93.8%)	24/25 (96.0%)	50/52 (96.2%)	21/22 (95.5%)	25/27 (92.6%)	46/48 (95.8%)
On Time	343/381 (90.0%)	29/30 (96.7%)	23/24 (95.8%)	46/50 (92.0%)	17/21 (81.0%)	23/25 (92.0%)	37/46 (80.4%)
Late	38/381 (10.0%)	1/30 (3.3%)	1/24 (4.2%)	4/50 (8.0%)	4/21 (19.0%)	2/25 (8.0%)	9/46 (19.6%)
MissedVisit	14/406 (3.4%)	0/32 (0.0%)	0/25 (0.0%)	1/52 (1.9%)	1/22 (4.5%)	0/27 (0.0%)	1/48 (2.1%)
Lost to Follow-up	11/406 (2.7%)	2/32 (6.3%)	1/25 (4.0%)	1/52 (1.9%)	0/22 (0.0%)	2/27 (7.4%)	1/48 (2.1%)
Week 24							
Evaluated	406	32	25	52	22	27	48
Retained	371/406 (91.4%)	30/32 (93.8%)	24/25 (96.0%)	50/52 (96.2%)	20/22 (90.9%)	24/27 (88.9%)	45/48 (93.8%)
On Time	321/371 (86.5%)	27/30 (90.0%)	24/24 (100.0%)	45/50 (90.0%)	18/20 (90.0%)	21/24 (87.5%)	38/45 (84.4%)
Late	50/371 (13.5%)	3/30 (10.0%)	0/24 (0.0%)	5/50 (10.0%)	2/20 (10.0%)	3/24 (12.5%)	7/45 (15.6%)
MissedVisit	24/406 (5.9%)	0/32 (0.0%)	0/25 (0.0%)	1/52 (1.9%)	2/22 (9.1%)	1/27 (3.7%)	2/48 (4.2%)
Lost to Follow-up	11/406 (2.7%)	2/32 (6.3%)	1/25 (4.0%)	1/52 (1.9%)	0/22 (0.0%)	2/27 (7.4%)	1/48 (2.1%)
Week 32							
Evaluated	406	32	25	52	22	27	48
Retained	361/406 (88.9%)	29/32 (90.6%)	23/25 (92.0%)	48/52 (92.3%)	19/22 (86.4%)	24/27 (88.9%)	41/48 (85.4%)
On Time	293/361 (81.2%)	28/29 (96.6%)	22/23 (95.7%)	44/48 (91.7%)	13/19 (68.4%)	21/24 (87.5%)	31/41 (75.6%)
Late	68/361 (18.8%)	1/29 (3.4%)	1/23 (4.3%)	4/48 (8.3%)	6/19 (31.6%)	3/24 (12.5%)	10/41 (24.4%)
MissedVisit	26/406 (6.4%)	0/32 (0.0%)	0/25 (0.0%)	3/52 (5.8%)	3/22 (13.6%)	1/27 (3.7%)	5/48 (10.4%)
Lost to Follow-up	19/406 (4.7%)	3/32 (9.4%)	2/25 (8.0%)	1/52 (1.9%)	0/22 (0.0%)	2/27 (7.4%)	2/48 (4.2%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.

Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.4 (01FEB2016,1:27)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
MALE**

	Total	Philadelphia, PA	Pittsburgh, PA	San Francisco, CA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	406	32	25	52	22	27	48
Week 40							
Evaluated	406	32	25	52	22	27	48
Retained	353/406 (86.9%)	29/32 (90.6%)	23/25 (92.0%)	46/52 (88.5%)	19/22 (86.4%)	22/27 (81.5%)	42/48 (87.5%)
On Time	283/353 (80.2%)	26/29 (89.7%)	23/23 (100.0%)	41/46 (89.1%)	13/19 (68.4%)	18/22 (81.8%)	26/42 (61.9%)
Late	70/353 (19.8%)	3/29 (10.3%)	0/23 (0.0%)	5/46 (10.9%)	6/19 (31.6%)	4/22 (18.2%)	16/42 (38.1%)
MissedVisit	33/406 (8.1%)	0/32 (0.0%)	0/25 (0.0%)	4/52 (7.7%)	3/22 (13.6%)	3/27 (11.1%)	4/48 (8.3%)
Lost to Follow-up	20/406 (4.9%)	3/32 (9.4%)	2/25 (8.0%)	2/52 (3.8%)	0/22 (0.0%)	2/27 (7.4%)	2/48 (4.2%)
Week 48							
Evaluated	406	32	25	52	22	27	48
Retained	340/406 (83.7%)	29/32 (90.6%)	23/25 (92.0%)	42/52 (80.8%)	19/22 (86.4%)	22/27 (81.5%)	39/48 (81.3%)
On Time	279/340 (82.1%)	25/29 (86.2%)	22/23 (95.7%)	37/42 (88.1%)	12/19 (63.2%)	17/22 (77.3%)	38/39 (97.4%)
Late	61/340 (17.9%)	4/29 (13.8%)	1/23 (4.3%)	5/42 (11.9%)	7/19 (36.8%)	5/22 (22.7%)	1/39 (2.6%)
MissedVisit	34/406 (8.4%)	0/32 (0.0%)	0/25 (0.0%)	7/52 (13.5%)	2/22 (9.1%)	2/27 (7.4%)	2/48 (4.2%)
Lost to Follow-up	32/406 (7.9%)	3/32 (9.4%)	2/25 (8.0%)	3/52 (5.8%)	1/22 (4.5%)	3/27 (11.1%)	7/48 (14.6%)
Week 49							
Evaluated	406	32	25	52	22	27	48
Retained	336/406 (82.8%)	29/32 (90.6%)	23/25 (92.0%)	43/52 (82.7%)	19/22 (86.4%)	20/27 (74.1%)	40/48 (83.3%)
On Time	236/336 (70.2%)	18/29 (62.1%)	20/23 (87.0%)	33/43 (76.7%)	11/19 (57.9%)	15/20 (75.0%)	32/40 (80.0%)
Late	100/336 (29.8%)	11/29 (37.9%)	3/23 (13.0%)	10/43 (23.3%)	8/19 (42.1%)	5/20 (25.0%)	8/40 (20.0%)
MissedVisit	34/406 (8.4%)	0/32 (0.0%)	0/25 (0.0%)	6/52 (11.5%)	2/22 (9.1%)	3/27 (11.1%)	1/48 (2.1%)
Lost to Follow-up	36/406 (8.9%)	3/32 (9.4%)	2/25 (8.0%)	3/52 (5.8%)	1/22 (4.5%)	4/27 (14.8%)	7/48 (14.6%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
FEMALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
N Enrolled	188	8	15	21	18	5	16
Week 2							
Evaluated	188	8	15	21	18	5	16
Retained	177/188 (94.1%)	8/8 (100.0%)	13/15 (86.7%)	20/21 (95.2%)	16/18 (88.9%)	5/5 (100.0%)	14/16 (87.5%)
On Time	173/177 (97.7%)	8/8 (100.0%)	13/13 (100.0%)	20/20 (100.0%)	16/16 (100.0%)	5/5 (100.0%)	13/14 (92.9%)
Late	4/177 (2.3%)	0/8 (0.0%)	0/13 (0.0%)	0/20 (0.0%)	0/16 (0.0%)	0/5 (0.0%)	1/14 (7.1%)
MissedVisit	10/188 (5.3%)	0/8 (0.0%)	2/15 (13.3%)	1/21 (4.8%)	2/18 (11.1%)	0/5 (0.0%)	2/16 (12.5%)
Lost to Follow-up	1/188 (0.5%)	0/8 (0.0%)	0/15 (0.0%)	0/21 (0.0%)	0/18 (0.0%)	0/5 (0.0%)	0/16 (0.0%)
Week 4							
Evaluated	188	8	15	21	18	5	16
Retained	178/188 (94.7%)	8/8 (100.0%)	14/15 (93.3%)	20/21 (95.2%)	18/18 (100.0%)	4/5 (80.0%)	15/16 (93.8%)
On Time	168/178 (94.4%)	8/8 (100.0%)	14/14 (100.0%)	20/20 (100.0%)	15/18 (83.3%)	4/4 (100.0%)	15/15 (100.0%)
Late	10/178 (5.6%)	0/8 (0.0%)	0/14 (0.0%)	0/20 (0.0%)	3/18 (16.7%)	0/4 (0.0%)	0/15 (0.0%)
MissedVisit	9/188 (4.8%)	0/8 (0.0%)	1/15 (6.7%)	1/21 (4.8%)	0/18 (0.0%)	1/5 (20.0%)	1/16 (6.3%)
Lost to Follow-up	1/188 (0.5%)	0/8 (0.0%)	0/15 (0.0%)	0/21 (0.0%)	0/18 (0.0%)	0/5 (0.0%)	0/16 (0.0%)
Week 8							
Evaluated	188	8	15	21	18	5	16
Retained	180/188 (95.7%)	8/8 (100.0%)	13/15 (86.7%)	20/21 (95.2%)	18/18 (100.0%)	4/5 (80.0%)	15/16 (93.8%)
On Time	167/180 (92.8%)	8/8 (100.0%)	9/13 (69.2%)	20/20 (100.0%)	16/18 (88.9%)	4/4 (100.0%)	15/15 (100.0%)
Late	13/180 (7.2%)	0/8 (0.0%)	4/13 (30.8%)	0/20 (0.0%)	2/18 (11.1%)	0/4 (0.0%)	0/15 (0.0%)
MissedVisit	6/188 (3.2%)	0/8 (0.0%)	1/15 (6.7%)	1/21 (4.8%)	0/18 (0.0%)	1/5 (20.0%)	1/16 (6.3%)
Lost to Follow-up	2/188 (1.1%)	0/8 (0.0%)	1/15 (6.7%)	0/21 (0.0%)	0/18 (0.0%)	0/5 (0.0%)	0/16 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.4 (01FEB2016,1:27)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
FEMALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
Week 16							
Evaluated	188	8	15	21	18	5	16
Retained	172/188 (91.5%)	8/8 (100.0%)	13/15 (86.7%)	20/21 (95.2%)	17/18 (94.4%)	4/5 (80.0%)	15/16 (93.8%)
On Time	152/172 (88.4%)	8/8 (100.0%)	9/13 (69.2%)	18/20 (90.0%)	17/17 (100.0%)	4/4 (100.0%)	14/15 (93.3%)
Late	20/172 (11.6%)	0/8 (0.0%)	4/13 (30.8%)	2/20 (10.0%)	0/17 (0.0%)	0/4 (0.0%)	1/15 (6.7%)
MissedVisit	10/188 (5.3%)	0/8 (0.0%)	1/15 (6.7%)	0/21 (0.0%)	1/18 (5.6%)	1/5 (20.0%)	1/16 (6.3%)
Lost to Follow-up	6/188 (3.2%)	0/8 (0.0%)	1/15 (6.7%)	1/21 (4.8%)	0/18 (0.0%)	0/5 (0.0%)	0/16 (0.0%)
Week 24							
Evaluated	188	8	15	21	18	5	16
Retained	167/188 (88.8%)	8/8 (100.0%)	12/15 (80.0%)	20/21 (95.2%)	17/18 (94.4%)	4/5 (80.0%)	14/16 (87.5%)
On Time	140/167 (83.8%)	7/8 (87.5%)	6/12 (50.0%)	18/20 (90.0%)	15/17 (88.2%)	2/4 (50.0%)	13/14 (92.9%)
Late	27/167 (16.2%)	1/8 (12.5%)	6/12 (50.0%)	2/20 (10.0%)	2/17 (11.8%)	2/4 (50.0%)	1/14 (7.1%)
MissedVisit	12/188 (6.4%)	0/8 (0.0%)	1/15 (6.7%)	0/21 (0.0%)	1/18 (5.6%)	1/5 (20.0%)	1/16 (6.3%)
Lost to Follow-up	9/188 (4.8%)	0/8 (0.0%)	2/15 (13.3%)	1/21 (4.8%)	0/18 (0.0%)	0/5 (0.0%)	1/16 (6.3%)
Week 32							
Evaluated	188	8	15	21	18	5	16
Retained	159/188 (84.6%)	7/8 (87.5%)	11/15 (73.3%)	18/21 (85.7%)	17/18 (94.4%)	4/5 (80.0%)	14/16 (87.5%)
On Time	133/159 (83.6%)	7/7 (100.0%)	8/11 (72.7%)	15/18 (83.3%)	14/17 (82.4%)	2/4 (50.0%)	11/14 (78.6%)
Late	26/159 (16.4%)	0/7 (0.0%)	3/11 (27.3%)	3/18 (16.7%)	3/17 (17.6%)	2/4 (50.0%)	3/14 (21.4%)
MissedVisit	16/188 (8.5%)	0/8 (0.0%)	2/15 (13.3%)	1/21 (4.8%)	1/18 (5.6%)	1/5 (20.0%)	1/16 (6.3%)
Lost to Follow-up	13/188 (6.9%)	1/8 (12.5%)	2/15 (13.3%)	2/21 (9.5%)	0/18 (0.0%)	0/5 (0.0%)	1/16 (6.3%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
FEMALE**

	Total	Baltimore, MD	Boston, MA	Chapel Hill/ Raleigh, NC	Cleveland, OH	Los Angeles, CA	New York, NY
Week 40							
Evaluated	188	8	15	21	18	5	16
Retained	162/188 (86.2%)	7/8 (87.5%)	11/15 (73.3%)	18/21 (85.7%)	17/18 (94.4%)	4/5 (80.0%)	14/16 (87.5%)
On Time	141/162 (87.0%)	7/7 (100.0%)	9/11 (81.8%)	17/18 (94.4%)	14/17 (82.4%)	2/4 (50.0%)	13/14 (92.9%)
Late	21/162 (13.0%)	0/7 (0.0%)	2/11 (18.2%)	1/18 (5.6%)	3/17 (17.6%)	2/4 (50.0%)	1/14 (7.1%)
MissedVisit	10/188 (5.3%)	0/8 (0.0%)	1/15 (6.7%)	1/21 (4.8%)	1/18 (5.6%)	1/5 (20.0%)	0/16 (0.0%)
Lost to Follow-up	16/188 (8.5%)	1/8 (12.5%)	3/15 (20.0%)	2/21 (9.5%)	0/18 (0.0%)	0/5 (0.0%)	2/16 (12.5%)
Week 48							
Evaluated	188	8	15	21	18	5	16
Retained	160/188 (85.1%)	7/8 (87.5%)	11/15 (73.3%)	16/21 (76.2%)	17/18 (94.4%)	4/5 (80.0%)	14/16 (87.5%)
On Time	140/160 (87.5%)	7/7 (100.0%)	8/11 (72.7%)	15/16 (93.8%)	15/17 (88.2%)	3/4 (75.0%)	14/14 (100.0%)
Late	20/160 (12.5%)	0/7 (0.0%)	3/11 (27.3%)	1/16 (6.3%)	2/17 (11.8%)	1/4 (25.0%)	0/14 (0.0%)
MissedVisit	10/188 (5.3%)	0/8 (0.0%)	1/15 (6.7%)	3/21 (14.3%)	1/18 (5.6%)	1/5 (20.0%)	0/16 (0.0%)
Lost to Follow-up	18/188 (9.6%)	1/8 (12.5%)	3/15 (20.0%)	2/21 (9.5%)	0/18 (0.0%)	0/5 (0.0%)	2/16 (12.5%)
Week 49							
Evaluated	188	8	15	21	18	5	16
Retained	153/188 (81.4%)	7/8 (87.5%)	8/15 (53.3%)	16/21 (76.2%)	17/18 (94.4%)	4/5 (80.0%)	14/16 (87.5%)
On Time	119/153 (77.8%)	7/7 (100.0%)	4/8 (50.0%)	13/16 (81.3%)	14/17 (82.4%)	4/4 (100.0%)	12/14 (85.7%)
Late	34/153 (22.2%)	0/7 (0.0%)	4/8 (50.0%)	3/16 (18.8%)	3/17 (17.6%)	0/4 (0.0%)	2/14 (14.3%)
MissedVisit	13/188 (6.9%)	0/8 (0.0%)	4/15 (26.7%)	3/21 (14.3%)	1/18 (5.6%)	1/5 (20.0%)	0/16 (0.0%)
Lost to Follow-up	22/188 (11.7%)	1/8 (12.5%)	3/15 (20.0%)	2/21 (9.5%)	0/18 (0.0%)	0/5 (0.0%)	2/16 (12.5%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.4 (01FEB2016,1:27)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
FEMALE**

	Total	Newark, NJ	Philadelphia, PA	Pittsburgh, PA	San Juan, PR	Seattle, WA	Washington DC
N Enrolled	188	32	15	15	15	8	20
Week 2							
Evaluated	188	32	15	15	15	8	20
Retained	177/188 (94.1%)	31/32 (96.9%)	15/15 (100.0%)	14/15 (93.3%)	14/15 (93.3%)	8/8 (100.0%)	19/20 (95.0%)
On Time	173/177 (97.7%)	31/31 (100.0%)	14/15 (93.3%)	14/14 (100.0%)	14/14 (100.0%)	6/8 (75.0%)	19/19 (100.0%)
Late	4/177 (2.3%)	0/31 (0.0%)	1/15 (6.7%)	0/14 (0.0%)	0/14 (0.0%)	2/8 (25.0%)	0/19 (0.0%)
MissedVisit	10/188 (5.3%)	1/32 (3.1%)	0/15 (0.0%)	0/15 (0.0%)	1/15 (6.7%)	0/8 (0.0%)	1/20 (5.0%)
Lost to Follow-up	1/188 (0.5%)	0/32 (0.0%)	0/15 (0.0%)	1/15 (6.7%)	0/15 (0.0%)	0/8 (0.0%)	0/20 (0.0%)
Week 4							
Evaluated	188	32	15	15	15	8	20
Retained	178/188 (94.7%)	31/32 (96.9%)	14/15 (93.3%)	14/15 (93.3%)	13/15 (86.7%)	8/8 (100.0%)	19/20 (95.0%)
On Time	168/178 (94.4%)	31/31 (100.0%)	13/14 (92.9%)	14/14 (100.0%)	13/13 (100.0%)	5/8 (62.5%)	16/19 (84.2%)
Late	10/178 (5.6%)	0/31 (0.0%)	1/14 (7.1%)	0/14 (0.0%)	0/13 (0.0%)	3/8 (37.5%)	3/19 (15.8%)
MissedVisit	9/188 (4.8%)	1/32 (3.1%)	1/15 (6.7%)	0/15 (0.0%)	2/15 (13.3%)	0/8 (0.0%)	1/20 (5.0%)
Lost to Follow-up	1/188 (0.5%)	0/32 (0.0%)	0/15 (0.0%)	1/15 (6.7%)	0/15 (0.0%)	0/8 (0.0%)	0/20 (0.0%)
Week 8							
Evaluated	188	32	15	15	15	8	20
Retained	180/188 (95.7%)	31/32 (96.9%)	14/15 (93.3%)	14/15 (93.3%)	15/15 (100.0%)	8/8 (100.0%)	20/20 (100.0%)
On Time	167/180 (92.8%)	29/31 (93.5%)	13/14 (92.9%)	14/14 (100.0%)	15/15 (100.0%)	8/8 (100.0%)	16/20 (80.0%)
Late	13/180 (7.2%)	2/31 (6.5%)	1/14 (7.1%)	0/14 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	4/20 (20.0%)
MissedVisit	6/188 (3.2%)	1/32 (3.1%)	1/15 (6.7%)	0/15 (0.0%)	0/15 (0.0%)	0/8 (0.0%)	0/20 (0.0%)
Lost to Follow-up	2/188 (1.1%)	0/32 (0.0%)	0/15 (0.0%)	1/15 (6.7%)	0/15 (0.0%)	0/8 (0.0%)	0/20 (0.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.4 (01FEB2016,1:27)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
FEMALE**

	Total	Newark, NJ	Philadelphia, PA	Pittsburgh, PA	San Juan, PR	Seattle, WA	Washington DC
Week 16							
Evaluated	188	32	15	15	15	8	20
Retained	172/188 (91.5%)	31/32 (96.9%)	14/15 (93.3%)	13/15 (86.7%)	12/15 (80.0%)	7/8 (87.5%)	18/20 (90.0%)
On Time	152/172 (88.4%)	31/31 (100.0%)	12/14 (85.7%)	13/13 (100.0%)	9/12 (75.0%)	5/7 (71.4%)	12/18 (66.7%)
Late	20/172 (11.6%)	0/31 (0.0%)	2/14 (14.3%)	0/13 (0.0%)	3/12 (25.0%)	2/7 (28.6%)	6/18 (33.3%)
MissedVisit	10/188 (5.3%)	1/32 (3.1%)	1/15 (6.7%)	1/15 (6.7%)	2/15 (13.3%)	1/8 (12.5%)	0/20 (0.0%)
Lost to Follow-up	6/188 (3.2%)	0/32 (0.0%)	0/15 (0.0%)	1/15 (6.7%)	1/15 (6.7%)	0/8 (0.0%)	2/20 (10.0%)
Week 24							
Evaluated	188	32	15	15	15	8	20
Retained	167/188 (88.8%)	30/32 (93.8%)	14/15 (93.3%)	13/15 (86.7%)	11/15 (73.3%)	7/8 (87.5%)	17/20 (85.0%)
On Time	140/167 (83.8%)	30/30 (100.0%)	13/14 (92.9%)	12/13 (92.3%)	8/11 (72.7%)	4/7 (57.1%)	12/17 (70.6%)
Late	27/167 (16.2%)	0/30 (0.0%)	1/14 (7.1%)	1/13 (7.7%)	3/11 (27.3%)	3/7 (42.9%)	5/17 (29.4%)
MissedVisit	12/188 (6.4%)	2/32 (6.3%)	0/15 (0.0%)	1/15 (6.7%)	3/15 (20.0%)	1/8 (12.5%)	1/20 (5.0%)
Lost to Follow-up	9/188 (4.8%)	0/32 (0.0%)	1/15 (6.7%)	1/15 (6.7%)	1/15 (6.7%)	0/8 (0.0%)	2/20 (10.0%)
Week 32							
Evaluated	188	32	15	15	15	8	20
Retained	159/188 (84.6%)	31/32 (96.9%)	13/15 (86.7%)	13/15 (86.7%)	10/15 (66.7%)	6/8 (75.0%)	15/20 (75.0%)
On Time	133/159 (83.6%)	28/31 (90.3%)	12/13 (92.3%)	13/13 (100.0%)	9/10 (90.0%)	3/6 (50.0%)	11/15 (73.3%)
Late	26/159 (16.4%)	3/31 (9.7%)	1/13 (7.7%)	0/13 (0.0%)	1/10 (10.0%)	3/6 (50.0%)	4/15 (26.7%)
MissedVisit	16/188 (8.5%)	1/32 (3.1%)	1/15 (6.7%)	1/15 (6.7%)	4/15 (26.7%)	2/8 (25.0%)	1/20 (5.0%)
Lost to Follow-up	13/188 (6.9%)	0/32 (0.0%)	1/15 (6.7%)	1/15 (6.7%)	1/15 (6.7%)	0/8 (0.0%)	4/20 (20.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.4 (01FEB2016,1:27)

**HPTN 069 - Maraviroc Phase II PrEP
Data as of January 31, 2016**

**Retention by Study Visit and Site
FEMALE**

	Total	Newark, NJ	Philadelphia, PA	Pittsburgh, PA	San Juan, PR	Seattle, WA	Washington DC
Week 40							
Evaluated	188	32	15	15	15	8	20
Retained	162/188 (86.2%)	31/32 (96.9%)	13/15 (86.7%)	13/15 (86.7%)	12/15 (80.0%)	6/8 (75.0%)	16/20 (80.0%)
On Time	141/162 (87.0%)	29/31 (93.5%)	11/13 (84.6%)	13/13 (100.0%)	9/12 (75.0%)	3/6 (50.0%)	14/16 (87.5%)
Late	21/162 (13.0%)	2/31 (6.5%)	2/13 (15.4%)	0/13 (0.0%)	3/12 (25.0%)	3/6 (50.0%)	2/16 (12.5%)
MissedVisit	10/188 (5.3%)	1/32 (3.1%)	1/15 (6.7%)	1/15 (6.7%)	1/15 (6.7%)	2/8 (25.0%)	0/20 (0.0%)
Lost to Follow-up	16/188 (8.5%)	0/32 (0.0%)	1/15 (6.7%)	1/15 (6.7%)	2/15 (13.3%)	0/8 (0.0%)	4/20 (20.0%)
Week 48							
Evaluated	188	32	15	15	15	8	20
Retained	160/188 (85.1%)	30/32 (93.8%)	14/15 (93.3%)	13/15 (86.7%)	11/15 (73.3%)	7/8 (87.5%)	16/20 (80.0%)
On Time	140/160 (87.5%)	30/30 (100.0%)	9/14 (64.3%)	12/13 (92.3%)	8/11 (72.7%)	3/7 (42.9%)	16/16 (100.0%)
Late	20/160 (12.5%)	0/30 (0.0%)	5/14 (35.7%)	1/13 (7.7%)	3/11 (27.3%)	4/7 (57.1%)	0/16 (0.0%)
MissedVisit	10/188 (5.3%)	1/32 (3.1%)	0/15 (0.0%)	1/15 (6.7%)	2/15 (13.3%)	0/8 (0.0%)	0/20 (0.0%)
Lost to Follow-up	18/188 (9.6%)	1/32 (3.1%)	1/15 (6.7%)	1/15 (6.7%)	2/15 (13.3%)	1/8 (12.5%)	4/20 (20.0%)
Week 49							
Evaluated	188	32	15	15	15	8	20
Retained	153/188 (81.4%)	30/32 (93.8%)	13/15 (86.7%)	11/15 (73.3%)	12/15 (80.0%)	5/8 (62.5%)	16/20 (80.0%)
On Time	119/153 (77.8%)	29/30 (96.7%)	7/13 (53.8%)	9/11 (81.8%)	5/12 (41.7%)	2/5 (40.0%)	13/16 (81.3%)
Late	34/153 (22.2%)	1/30 (3.3%)	6/13 (46.2%)	2/11 (18.2%)	7/12 (58.3%)	3/5 (60.0%)	3/16 (18.8%)
MissedVisit	13/188 (6.9%)	1/32 (3.1%)	0/15 (0.0%)	1/15 (6.7%)	1/15 (6.7%)	1/8 (12.5%)	0/20 (0.0%)
Lost to Follow-up	22/188 (11.7%)	1/32 (3.1%)	2/15 (13.3%)	3/15 (20.0%)	2/15 (13.3%)	2/8 (25.0%)	4/20 (20.0%)

Retained includes all participants who have completed the visit, even those participants whose visit windows have not closed.
Denominator is the number of participants whose visit windows have closed plus the number of participants who have attended the visit even if their window hasn't closed.

Source: SCHARP (kate) - /trials/hptn/p069/reporting/progress/code/t_retention.sas, SAS Version 9.4 (01FEB2016,1:27)